Enhancing Oral Bioavailability of Cannabinoids

Friedman Michael, HUJI, School of Medicine - IMRIC, School of Pharmacy- Institute for Drug Research
Hoffman Amnon, HUJI, School of Medicine - IMRIC, School of Pharmacy- Institute for Drug Research


Prolonged release oral tablets   


Cannabinoids, Cannabis, tablets, oral administration



In recent years, the medical use of cannabis and its derivatives has become widely accepted in the medical profession.  IN addition, policy changes throughout many countries now allow for cannabis to be prescribed for medicinal purposes. For reasons of patient compliance as well as to control the side effects, there is a rising need for an oral controlled release cannabinoid formulation. Cannabinoids, however, are not candidates for classical controlled release delivery systems, because the extremely lipophilic characteristics of THC and CBD limit their absorption along the intestine.

Our Innovation

We suggest a novel solid dosage form that enables the controlled release of cannabinoids by using gastro retentive tablets. These formulations are designed sit in the stomach for a prolonged period of time, allowing the release of their drug load in a continuous manner. Subsequently, the patient will retain prolonged active blood levels that lead to benefits such as:

  • Fewer side effects associated with the peaks and lows of IR formulations
  • Superior patient compliance


The proposed Gastro-Retentive Tablets are a platform technology relevant for various therapeutic indications. They offer the advantage of oral administration along with both a controlled and prolonged release of cannabinoids.

Patent Status

Published WO 2021/137225

Contact for more information:

Ariela Markel
VP, Business Development, Healthcare